Long-term clinical value and outcome of riociguat in chronic thromboembolic pulmonary hypertension
Background: To improve clinical outcome, patients with inoperable and residual chronic thromboembolic pulmonary hypertension (CTEPH) can be treated with riociguat. The aim of this study is to explore long-term outcomes and to compare our ‘real world’ data with previous research. Methods: We included...
Main Authors: | M.C.J. van Thor, L. ten Klooster, R.J. Snijder, M.C. Post, J.J. Mager |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-03-01
|
Series: | International Journal of Cardiology: Heart & Vasculature |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2352906719300144 |
Similar Items
-
Does combination therapy work in chronic thromboembolic pulmonary hypertension?
by: M.C.J. van Thor, et al.
Published: (2020-08-01) -
Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hypertension?
by: N. H. Kim
Published: (2010-03-01) -
Cost-effectiveness of riociguat and bosentan for the treatment of chronic thromboembolic pulmonary hypertension
by: Ashaye, Ajibade O.
Published: (2018) -
Inoperable chronic thromboembolic pulmonary hypertension treated with riociguat: A case studyInoperable chronic thromboembolic pulmonary hypertension
by: Carlos Ortiz-Bautista, et al.
Published: (2015-12-01) -
Riociguat is a novel medication for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
by: N. A. Tsareva, et al.
Published: (2016-12-01)